Systemic Lupus Erythematosus — CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus
Citation(s)
A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)